Science

Mihaela Stana: The spectrum of adverse events during mBC treatment with ADCs

Mihaela Stana/LinkedIn

Feb 20, 2025, 09:40

Mihaela Stana: The spectrum of adverse events during mBC treatment with ADCs

Mihaela Stana, Oncology Specialist at Elysee Hospital, shared a post on LinkedIn about a paper she co-authored with colleagues published in European Journal of Clinical Oncology:

“Biggest thanks to Matteo Lambertini and the team Marta Perachino, Luca Arecco, Eva Blondeaux, Kristina Janković, Elene Mariamidze for our new article which approaches the spectrum of adverse events during metastatic breast cancer treatment with ADCs and their impact on QoL.

To check the complete results, you can access the paper.”

“Adverse events and impact on quality of life of antibody-drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta-analysis”

Authors: Matteo Lambertini, Mihaela Stana, Marta Perachino, Luca Arecco, Eva Blondeaux, Kristina Janković, Elene Mariamidze et al.

Mihaela Stana: The spectrum of adverse events during mBC treatment with ADCs

cancer Elene Mariamidze Eva Blondeaux Kristina Jankovic Luca Arecco Marta Perachino Matteo Lambertini metastatic breast cancer Mihaela Stana OncoDaily Oncology

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025

China Approved DATROWAY (Datopotamab Deruxtecan) for HR-Positive, HER2-Negative Metastatic Breast Cancer

Simon Mooijaart: Patient Perspectives on Antithrombotic Therapy in Advanced Cancer

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?